Effectiveness of N-Acetylcysteine in the Treatment of Renal Deterioration Caused by Long-Term Exposure to Bisphenol A

Human health hazards caused by bisphenol A (BPA), a precursor for epoxy resins and polycarbonate-based plastics, are well documented and are closely associated with mitochondrial impairment and oxidative imbalance. This study aimed to assess the therapeutic efficacy of N-acetylcysteine (NAC) on renal deterioration caused by long-term BPA exposure and examine the signaling transduction pathway involved. Male Wistar rats were given vehicle or BPA orally for 12 weeks then the BPA-treated group was subdivided to receive vehicle or NAC concurrently with BPA for a further 4 weeks, while the vehicle-treated normal control group continued to receive vehicle through to the end of experiment. Proteinuria, azotemia, glomerular filtration reduction and histopathological abnormalities caused by chronic BPA exposure were significantly reduced following NAC therapy. NAC also diminished nitric oxide and lipid peroxidation but enhanced renal glutathione levels, and counteracted BPA-induced mitochondrial swelling, increased mitochondrial reactive oxygen species production, and the loss of mitochondrial membrane potential. The benefit of NAC was related to the modulation of signaling proteins in the AMPK-SIRT3-SOD2 axis. The present study shows the potential of NAC to restore mitochondrial integrity and oxidative balance after long-term BPA exposure, and suggests that NAC therapy is an effective approach to tackle renal deterioration in this condition.

Presumed masitinib-induced nephrotic syndrome and azotemia in a dog

Masitinib mesylate is a tyrosine-kinase inhibitor approved for the treatment of nonresectable or recurrent, Grade 2 or 3 mast cell tumors in dogs. This report describes nephrotic syndrome and acute kidney injury attributed to masitinib and illustrates the need for regular monitoring of serum creatinine concentration, urinalysis, and urine protein:creatinine ratio during its use.

[Retrospective study on the effects of a whey protein concentrate on body composition in 262 sarcopenic tube fed patients]

AIM

As pointed in ESPEN guidelines on the use of bioelectrical impedance analysis (BIA), "body cell mass (BCM) is the protein rich compartment which is affected in catabolic states, and loss of BCM is associated with poor clinical outcome". Whey proteins are known to improve lean mass in many conditions. We retrospectively evaluated the effects of a WP concentrate with high cysteine content (WPHCC) on BCM of 262 sarcopenic tube fed patients (pts).

METHODS

Two hundred sixty-two sarcopenic tube fed pts (130 males, mean age 68,1±15,6 years) were given daily supplemental WPHCC (0.7±0.2 g/kg body weight) after their usual feeding formula, with the aim to improve their BCM. Each patient received a multifrequency impedance test before and after the beginning of WPHCC supplementation (mean follow-up: 4.2±2.8 months). Fifty percent of patients were affected by neurodegenerative diseases, 36% by cancer, 14% by other conditions.

RESULTS

BCM, body weight and fat mass significantly improved (P<0.01) after treatment. No severe side effects were recorded. A slight increase in blood urea was observed.

CONCLUSION

In our population WPHCC have been safe and effective in improving BCM. WPHCC could be useful to improve BCM in sarcopenic tube fed pts, although renal function should be monitored.